Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Aurintricarboxylic Acid Proposed as Basis of New Glioblastoma Treatment Plan

By BiotechDaily International staff writers
Posted on 01 Feb 2017
Print article
Image: A ball-and-stick model of the aurintricarboxylic acid (ATA) molecule (Photo courtesy of Wikimedia Commons).
Image: A ball-and-stick model of the aurintricarboxylic acid (ATA) molecule (Photo courtesy of Wikimedia Commons).
The compound aurintricarboxylic acid (ATA) has been identified as a possible new therapeutic agent for treatment of patients with the deadly brain cancer glioblastoma multiforme (GBM).

GBM is the most common primary tumor of the central nervous system and is almost always fatal. The aggressive invasion of GBM cells into the surrounding normal brain makes complete surgical removal impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Median survival for newly diagnosed GBM is 14.6 months and declines to eight months for patients with recurrent GBM. Treatment of glioblastoma usually comprises surgical removal of the tumor followed by radiation treatment and chemotherapy using the drug temozolomide (TMZ). However, the penetration of the tumor into adjacent brain tissue prevents the surgical removal of all tumor cells, which usually develop resistance to TMZ.

Investigators at the Translational Genomics Research Institute have been seeking a better approach for treating GBM. In previous studies they had found that development of GBM was linked to TWEAK (Tumor necrosis factor-like weak inducer of apoptosis), a member of the tumor necrosis factor (TNF) superfamily, which could stimulate glioma cell invasion and survival via binding to fibroblast growth factor-inducible 14 (Fn14) and subsequent activation of the transcription factor NF-kappaB.

In the current study, to discover small molecule inhibitors capable of disrupting the TWEAK-Fn14 signaling axis, the investigators utilized a cell-based drug-screening assay using HEK293 cells engineered to express both Fn14 and a NF-kappaB-driven firefly luciferase reporter protein.

The investigators reported in the January 17, 2017, online edition of the journal Oncotarget that during screening of 1280 pharmacologically active compounds they had identified aurintricarboxylic acid (ATA) as an agent that suppressed TWEAK-Fn14-NF-kappaB dependent signaling, but not TNFalpha-TNFR-NF-kappaB driven signaling. ATA is used to inhibit protein biosynthesis in its initial stages, and it is frequently used in biological experiments as a protein inhibitor.

The investigators showed that ATA repressed TWEAK-induced glioma cell chemotactic migration and invasion via inhibition of Rac1 activation but had no effect on cell viability or Fn14 expression. In addition, ATA treatment enhanced glioma cell sensitivity to both TMZ and radiation-induced cell death.

"These data demonstrate that ATA presents a scaffold structure that could be modified in ways to improve its properties and to develop as a potential therapeutic agent to limit invasion and enhance chemotherapeutic drug efficacy in GBM," said senior author Dr. Nhan Tran, associate professor of cancer and cell biology at the Translational Genomics Research Institute.


Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2017 Globetech Media. All rights reserved.